While the etiology of non-familial Parkinson’s disease (PD) remains unclear, there is evidence that increased levels of tissue iron may be a contributing factor. Moreover, exposure to some environmental toxicants is considered an additional risk factor. Therefore, brain-targeted iron chelators are of interest as antidotes for poisoning with dopaminergic toxicants, and as potential treatment of PD. We, therefore, designed a series of small molecules with high affinity for ferric iron and containing structural elements to allow their transport to the brain via the neutral amino acid transporter, LAT1 (SLC7A5). Five candidate molecules were synthesized and initially characterized for protection from ferroptosis in human neurons. The promising hydroxypyridinone SK4 was characterized further. Selective iron chelation within the physiological range of pH values and uptake by LAT1 were confirmed. Concentrations of 10–20 µM blocked neurite loss and cell demise triggered by the parkinsonian neurotoxicants, methyl-phenyl-pyridinium (MPP+) and 6-hydroxydopamine (6-OHDA) in human dopaminergic neuronal cultures (LUHMES cells). Rescue was also observed when chelators were given after the toxicant. SK4 derivatives that either lacked LAT1 affinity or had reduced iron chelation potency showed altered activity in our assay panel, as expected. Thus, an iron chelator was developed that revealed neuroprotective properties, as assessed in several models. The data strongly support the role of iron in dopaminergic neurotoxicity and suggests further exploration of the proposed design strategy for improving brain iron chelation.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (AD), affecting 1–2% of the population over 65 years of age (de Rijk et al. 2000). It has been estimated that the number of PD cases will double by 2030 (Dorsey et al. 2007), making identification and development of therapeutic agents to prevent, halt or slow down the processes associated with PD neuropathology an urgent aim. The disease is primarily caused by the loss of dopaminergic neurons in the Substantia nigra pars compacta (SNpc) (Lees 2009). Although the exact etiology of neuronal loss is unclear, several contributing factors have been suggested, including intracellular deposition of abnormally aggregated alpha-synuclein protein (α-SYN) that forms a major constituent of so-called ‘Lewy bodies’ (Schildknecht et al. 2013). In association with pathological α-SYN, both impaired proteostasis and mitochondrial dysfunction have been deemed critical drivers of PD pathogenesis (Malkus et al. 2009; Vigouroux et al. 2004; Zabel et al. 2010). Toxicants like methyl-phenyl-tetrahydropyridine (MPTP) can cause human pathology that highly resembles PD (Schildknecht et al. 2017). The history of accidental poisoning with MPTP, which is a contaminant of some illicit drug preparations, has been extensively documented (William Langston 1985). Several environmental agents, such as maneb, dieldrin, paraquat or tebufenpyrad have been examined for potential roles in PD pathology. For some of these pesticides, in particular for the piscicide rotenone, a statistically significant correlation of exposure and disease has been found both in epidemiological studies and in animal experiments (Greenamyre and Hastings 2004; Terron et al. 2018).
Following the initial observation by Lhermitte and others (Lhermitte et al. 1924) of abnormal accumulation of the redox-active biometal, iron within the basal ganglia of PD-affected post-mortem brains, the question arose whether disrupted iron metabolism is either adaptive or disease promoting (Kaur and Andersen 2004). As iron promotes the generation of highly aggressive free radicals via the Haber–Weiss cycle/Fenton reaction (Schildknecht et al. 2013), abnormal accumulation of redox-active metal in the brain could play a central role in PD neuropathology. In this regard, it was suggested that oxidation of iron to the ferric state may drive a vicious circle between excessive pathological levels of reactive oxygen species (ROS), and the intracellular deposition of aggregated α-SYN (Febbraro et al. 2012; Levin et al. 2009; Schildknecht et al. 2013).
The finding that iron accumulates in SNpc-located dopaminergic neurons during PD progression has prompted studies for testing whether iron chelation may be capable of modifying PD progression (Devos et al. 2014; Dusek et al. 2016). Recently, a pilot clinical trial assessed the orally available 3-hydroxy-4(1H)-pyridinone (3,4-HOPO)-based iron chelator, deferiprone (DFP) (Devos et al. 2014). Early-stage PD patients treated for six months showed decreased SNpc iron content, which associated with slowed disease progression, indicated by motor scores. In a follow-up study, the authors reported that 6–12 months of DFP treatment resulted in reduced SN iron levels and also improved Unified Parkinson Disease Rating Scale (UPDRS) scores in early-stage PD patients (Grolez et al. 2015). The authors further reported that PD patients with low serum activity levels of ceruloplasmin, a ferroxidase enzyme important for iron metabolism, responded better to iron chelation therapy. In other work, Martin-Bastida and colleagues (Martin-Bastida et al. 2017) found that DFP has low efficacy for removing iron from the SNpc. The authors further reported only moderate (non-significant) motor symptom improvements in PD patients treated with 30 mg/kg deferiprone. The conflicting results reported in published literature regarding the clinical efficacy of iron chelators against PD-related neurodegeneration calls for further preclinical studies using robust models of the disease to validate and assess the mechanisms of neuroprotection. Moreover, it calls for efforts to explore other, possibly more effective, iron chelators.
The therapeutic efficacy of iron chelators against neurodegenerative disease may be further improved by promoting their uptake into the brain and by altering their affinity pattern for various relevant ions. With this in mind, we explored the anti-PD therapeutic potential of novel hydroxypyridinones (HOPOs) and related structures (Chaves et al. 2018; Workman et al. 2015). The compounds, termed SK1-SK5, were synthesized and assessed for their ability to attenuate dopaminergic neuronal death. As an in vitro screening system for assessing the neuroprotective capacity of the compounds, LUHMES cells were used. These human-derived mesencephalic neural precursor cells can be differentiated into post-mitotic dopaminergic neurons (Schildknecht et al. 2009; Scholz et al. 2011). Such cells have been frequently used in combination with PD-related toxicants to model PD neuropathology, including neuronal loss and intracytoplasmic protein aggregates (Devos et al. 2014; Efremova et al. 2015; Gutbier et al. 2018b; Harris et al. 2018; Hollerhage et al. 2017; Poltl et al. 2012; Schildknecht et al. 2009; Scholz et al. 2011).
The SK compounds were designed to be translocated across the blood–brain barrier (BBB) in a similar way as the PD drug levodopa, which is transported by the large amino acid transporter (LAT1), encoded by SLC7A5 genes (Dickens et al. 2017). As this carrier is known to accept aromatic amino acids, an amino acid side chain was added to the heterocyclic core structure (Singh and Ecker 2018). The rationale for this design feature was to allow brain penetration in high enough concentrations to achieve an anti-parkinsonian therapeutic effect, and thereby avoid excessive metabolism or side effects in the body periphery. Our screen revealed strong neuroprotective properties for one novel chelator in particular, the 3-hydroxy-4(1H)-pyridinone termed SK4, which validates abnormal levels of iron ions as a target for the development of novel therapeutic approaches for slowing PD-related neurodegeneration.
Materials and methods
Dibutyryl-cAMP (cAMP), fibronectin, Hoechst bisbenzimide H-33342, resazurin sodium salt, tetracycline and the neurotoxicants 1-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA) were purchased from Sigma-Aldrich (Steinheim, Germany). Recombinant human Fibroblast Growth Factor 2 (FGF-2) and recombinant human glial-derived neurotrophic factor (GDNF) were purchased from R&D Systems (Minneapolis, USA). Erastin was purchased from Selleckchem (Munich, Germany). Chemicals for the synthesis of the iron chelator and control compounds were purchased from either Sigma-Aldrich (Gillingham, UK), Acros Organics (Geel, Belgium) or Fluorochem (Hadfield, UK) and used without further purification, unless otherwise stated.
Synthesis of novel iron chelators
The synthesis and chemical characterization of precursor 1 (P1: (2L)-3-amino-2-([(tert-butoxy)carbonyl]amino)propanoic acid) and precursor 2 (P2: 3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one) was exactly as described in the literature, and is detailed in the supplementary methods and supplementary figure S1. Detailed synthesis protocols and chemical characterization of the SK compounds are found in the supplementary methods and supplementary figures S2–5. Exemplary data are provided here on SK4 ((2L)-amino-3-(3-hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-yl)propanoic acid): First 4.9 g (22.66 mmol) of P2 was mixed with 2.9 g (14.2 mmol) of P1, and dissolved in water (100 ml) plus ethanol (100 ml) containing sodium hydroxide (2 g, 50 mmol). The resulting solution was mixed at room temperature (RT) for 8 days continuously. The solution was then acidified to pH 2.0 by the addition of concentrated hydrochloric acid (HCl). Excess solvents were removed under reduced pressure. The resulting residue was mixed with hydrobromic acid (48% w/v, 20 ml) and refluxed for 20 min. The solution mixture was concentrated under reduced pressure, and then the resulting solid was dissolved in water (20 ml), followed by treatment with charcoal and basified (pH 5.0) by adding ammonium hydroxide solution (ammonia water). The resulting solution was cooled to 5 °C for 72 h, after which the brown crystals were precipitated. The crystals were collected, washed with water and dried, rendering the titled compound to become pale brown crystals (3.23 g, 14.27 mmol, 63%). Melting point (Mp): 165–168 oC. 1H-NMR (400 MHz, D2O/CF3COOD) δH = 1.90 (s, 3H), 3.85 (t, J = 7.2 Hz, 1H), 4.07–4.12 (m, 1H), 4.27–4.33 (m, 1H), 6.44 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H); 13C-NMR (100 MHz, D2O/CF3COOD) δC = 13.4, 49.17, 52.24, 119.54, 141.59, 143.28, 147.33, 170.96, 176.7. High-resolution mass spectrometry (MS) using electron spray ionization gave a measured weight (including 1 extra proton (M + H)) [M + H] of 213.0866 (theoretical [M + H] is 213.0869 for C9H12N2O4).
Metal binding studies
Metal cation solutions were prepared from their perchlorate salts and their concentrations were determined spectrophotometrically for Fe3+ or via colorimetric titrations (for Cu2+ and Zn2+) with EDTA (Titriplex III, Millipore), in accordance with published protocols (Fish 1988; Skoog and Skoog 2004). The acido-basic properties (pKa) of ligands SK2, SK3 and SK4 and their affinity for metals were determined via potentiometric titrations (Cu2+, Zn2+) and spectrophotometric titrations versus pH (Fe3+). The potentiometric titrations were carried out in water (I = 0.1 M NaClO4), in accordance with a previously published procedure (Gillet et al. 2017), using a 904 DMS Titrando automatic titrator system (Methrom AG; Herisau, Switzerland) with a 2-ml Dosino 800 burette driven by the TiAmo 2.5 software (Methrom AG; Herisau, Switzerland) and a combined glass electrode (6.0234.100; long life, Methrom AG; Herisau, Switzerland) filled with 0.1-M NaCl. The Fe3+ complexes were already fully formed at pH 2 and could, therefore, not be studied via this technique. The potentiometric data were refined with the Hyperquad 2008 program (Gans et al. 1996).
The protonation constants of the ligands SK2, SK3 and SK4, and their stability constants with Fe3+, were determined by ultraviolet (UV)–visible spectrophotometric titrations versus pH, by simultaneously recording pH and UV–visible spectra using a Metrohm UV–visible spectrophotometer (Cary 60 model, Agilent). Between pH = − 0.5 and 2, the batch technique was used; while, classical titrations were carried out for pH values between 2 and 12, following a published procedure (Gillet et al. 2017). The ionic strength was not fixed at pH < 1 in the batch titrations and no decomposition of the ligands was observed, even in strongly acidic conditions.
The spectrophotometric data were fitted with HypSpec software (Gans et al. 1996), accessible at https://www.hyperquad.co.uk, to calculate the protonation constants of the ligands, the stability constants (log ß) of the formed species and the co-ordination model of the studied systems. The data for Fe3+, Cu2+ and Zn2+ hydrated species and their solubility products were taken into account in the equilibrium model (Baes and Mesmer 1986).
LUHMES cells have a normal human genome, a dopaminergic phenotype, neurotypical electrophysiological properties and sensitivity to PD-related neurotoxicants, including rotenone, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and its metabolite MPP+. Handling of LUHMES cell cultures was performed as previously described (Gutbier et al. 2018a; Scholz et al. 2011). Briefly, the conditionally immortalized cells were maintained in proliferation medium (PM) that consisted of advanced Dulbecco's Modified Eagle Medium (DMEM)/F12, 2 mM l-glutamine, 1xN2 supplement (Invitrogen, CA, USA) and 40-ng/ml FGF-2, and were kept in a 5% CO2/95% air atmosphere at 37 °C. Cells were passaged every other day. For differentiation, 8 million cells were seeded in a Nunclon T175 tissue culture flask pre-coated with 50-µg/ml poly- l -ornithine (PLO) and 1-µg/ml fibronectin in water. After 24 h, the medium was changed to differentiation medium (DM), consisting of advanced DMEM/F12 supplemented with 2-mM l -glutamine, 1 × N2, 2.25-µM tetracycline, 1-mM dibutyryl 3′,5′-cyclic adenosine monophosphate (cAMP) and 2-ng/ml recombinant human GDNF. After 48 h, cells were trypsinised and seeded at a density of 1.5 × 105 cells/cm2 into dishes pre-coated with 50-µg/ml PLO and 1 µg/ml fibronectin in DM.
In vitro neurotoxicity models and compound treatment
LUHMES cells, differentiated into mature, post-mitotic dopaminergic neurons, were treated with one of the four neurotoxicants, to create well-characterized in vitro models of PD. Prior to neurotoxicant exposure, cells were treated with either an SK or control compound for 1 h before addition of the neurotoxicant. All compounds (using a stock concentration of 50 mM) were easily dissolvable in distilled H2O (dH2O) without requiring heating. The only exception was SK2, where the stock concentration was reduced to 5 mM, due to poor water solubility of the compound. SK and control compounds were applied to the cells at concentrations which ranged from 12.5 to 500 µM under standard incubator conditions (37 °C in a humidified 95% air, 5% CO2 atmosphere).
Following the preincubation period with a compound of interest, cells were treated with the parkinsonian mimetic, MPP+, the active metabolite of MPTP, which induces dopaminergic neuronal toxicity by inhibiting mitochondrial complex I activity (Dauer and Przedborski 2003). MPP+ (5 µM, Sigma), dissolved in dH2O, was applied to the cells for 72 h before further assessments.
Cells were also treated with the neurotoxicant 6-OHDA, which is relatively selective for uptake by dopaminergic neurons due to the high affinity such neurons’ plasma membrane transporters hold for this molecule (Luthman et al. 1989). In this neurotoxicant-induced model of cell death, neurodegeneration occurs principally by means of excessive generation of ROS, to ultimately evoke oxidative stress-related cytotoxicity (Blum et al. 2001). After the compound preincubation period, cells were treated with 100-µM 6-OHDA (Sigma-Aldrich), dissolved in dH2O. Cells were toxin-treated for 18 h, before further measures were taken.
Ferroptosis, a non-apoptotic form of iron-dependent cell death that occurs due to lethally high levels of lipid hydroperoxides (Stockwell et al. 2017) was initiated via application of the ferroptosis activator, erastin (Eradicator of RAS and Small T antigen-expressing cells). Similar to the other toxin cellular conditions, either an SK or a control compound was pre-applied to the cells for 1 h before exposure to erastin (which lasted 24 h). Erastin was applied to the cells at a concentration of 1.25 µM [10-mM stock in dimethyl sulfoxide (DMSO)], prediluted to 1:800, with the final concentration applied to the cells that was 1:10.
Finally, iron-mediated cell damage was initiated by the addition of ferrous sulfate. The cells were pretreated with an SK compound for 1 h. Fe2+SO4 was then added for a period of 4 days, after which viability was assessed via the Resazurin reduction assay. Neuronal morphology was also determined by staining the cells with an anti β-III-tubulin antibody (Sigma, rabbit, 1:1000) and then a secondary antibody (1:1000, anti-rabbit IgG Alexa Fluor 555; Invitrogen) for fluorescent (yellow) detection.
General cell viability endpoints
Resazurin: Metabolic activity was detected by means of a resazurin reduction assay. Briefly, resazurin solution was added to the cell culture medium to obtain a final concentration of 10 µg/ml. After incubating for 30 min at 37 °C, the fluorescence signal was measured at an excitation wavelength of 530 nm, using a 590-nm long-pass filter to record the emission. Fluorescence values were normalized by setting fluorescence values of untreated wells as 100%.
LDH release: In a separate assay, lactate dehydrogenase (LDH) activity was measured in the supernatant and in the corresponding cell homogenates. After the media had been transferred into separate plates, cells were lysed in PBS/0.1% Triton X-100 for 2 h. A total of 20 μl of sample was then added to 180 µl of reaction buffer containing nicotinamide adenine dinucleotide (NADH, 100 μM) and sodium pyruvate (600 μM) in potassium phosphate buffer (pH 7.4). Absorption at 340 nm was measured at 37 °C in 1-min intervals over a period of 15 min. The slope of NADH consumption was calculated. The ratio of LDHsupernatant/LDHtotal was calculated using the slopes of supernatant and homogenate. Control data were subtracted from LDH values. Final LDH release data is expressed as percentage of total LDH.
Neurite area as an indicator of cell viability
Calcein-AM: Labeling of live cells was performed with 1-µM Calcein-AM / 1-µg/ml Hoechst H-33342 for 30 min at 37 °C. Images were collected in two different fluorescent channels using an automated microscope (Array-Scan VTI HCS Reader; Thermo Fisher, PA, USA). Analysis was performed by epifluorescence imaging using an automated microplate-reading microscope (ArrayScan VI HCS Reader, Cellomics, Pittsburgh, PA, USA) equipped with a Hamamatsu ORCA-ER camera (resolution 1024 × 1024; run at 2 × 2 binning). Nuclei were identified as objects using channel 1 (365 ± 50/461 ± 15 nm) and according to their average size, area, shape and intensity. The calcein signal was detected in channel 2 (475 ± 40/525 ± 15 nm). An algorithm quantified all calcein-positive cells as viable and only Hoechst H-33342-positive nuclei as “not viable” cells. For evaluating the neurite areas, nuclei masks were first determined in channel 1, and then expanded and transferred to channel 2. All calcein-positive pixels lying outside of these masks (somatic area) were counted as neurite area.
Three-Dimensional neuronal organoids
Three-Dimensional (3D) neuronal organoids were generated by differentiating LUHMES cells for two days, as described for LUHMES cell culturing. On day 2 of differentiation, cells were detached and seeded in round-bottom ultra-low attachment 96-well plates (#7007, Corning Costar) at a cell density of 5000 cells/well in 100-µl LUHMES differentiation medium (DM). To facilitate spheroid formation, plates were centrifuged at RT for 5 min at 300 × g. Organoids formed spontaneously from the cell pellets within 48 h. Half medium was changed every 2–3 days. On day 8 of differentiation, LUHMES organoids were plated on Matrigel-coated (1:200) 96-well plates (#83.3924, Sarstedt) to allow neurite outgrowth. After 48 h, plated organoids were treated with the ferroptosis-inducer, erastin for 24 h, with or without 1 h pre-treatment with ferrostatin-1, the established neuroprotective iron chelator desferoxamine (DFO) (Poltl et al. 2012), or SK4, which the initial neuroprotective screen highlighted as a lead compound. Cell viability was determined using calcein-AM (1 µM) staining, while neurite area was determined by means of propidium iodide (1 µg/ml) staining, the staining reagents that were applied for 1 h. Mosaic fluorescent images were then taken of the cells using automated microscopy (Axio Observer A1, Carl Zeiss, Germany), which utilized an objective size 5x/0.15 EC Plan-Neofluor. Twelve images per well were taken and stitched together using Zeiss “Zen” imaging software (version 18.104.22.168, Blue edition). Images were analyzed using ImageJ software (version 1.51 s, Rasband, U.S. National Institutes of Health). Neurite area was calculated as the total neurite area, and cell viability as the relative propidium iodide fluorescence intensity to a positive 100% dead control (0.5% Triton-X100).
For immunostaining, plated spheres were fixed on an 8-well µ-slide (#80,826, Ibidi, Germany) with 4% paraformaldehyde (PFA) for 1 h at RT. After washing with phosphate-buffered saline (PBS), specimens were permeabilized with 0.6% Triton-X100 for 30 min at RT. Subsequently, they were blocked with blocking buffer (5% fetal bovine serum (FBS) and 0.1% Triton-X100 in PBS). Anti-NF200 primary antibody (#N0142, Sigma) was applied diluted in blocking buffer (1:1000) overnight at 4 °C. After washing with PBS, secondary antibody (#A2112, anti-mouse IgG1 Alexa Fluor 555, Invitrogen) was applied diluted in blocking buffer (1:1000) for 1 h at RT. Images were recorded with a Zeiss LSM 880 confocal microscope (40×/1.4 Plan apochromat, oil based) and processed in ImageJ.
LAT1-mediated uptake and trans-stimulation assay
HEK293 cells, stably expressing pcDNA3.1 V5-6xHis (control) or pcDNA3.1 SLC7A5-V5-6xHis (LAT1), were generated and cultured in DMEM containing 10% FBS (Dickens et al. 2013, 2017). HEK293 control and HEK293 LAT1 cells were plated 24 h before the transport assays were performed. The wells were washed with transport buffer [Hank’s buffered saline solution + 25 mM HEPES + 0.1% w/v bovine serum albumin (BSA) at pH 7.4] pre-warmed to 37 °C. 3[H]-phenylalanine [American Radiolabeled Chemicals (ARC), St. Louis, MO, USA] at a radiotracer concentration of 0.15 µCi/ml and unlabelled phenylalanine (ARC), giving a final concentration of 1 µM, was included in the transport buffer. This was added to the cells for 3 min at 37 °C in the absence/presence of 1-mM leucine, SK4 or SK4C2. At the end of the uptake assay the cells were washed 3 × with ice-cold transport buffer. Cell lysis was carried out by adding 5% w/v sodium dodecyl sulfate (SDS) for at least 15 min at 37 °C. Liquid scintillation (LS) counting on the cell lysates was performed with a 1500 Tri Carb LS counter (Packard Instrument Company, Germany). The LAT1-mediated uptake of phenylalanine is determined by subtracting the uptake of HEK293 control cells from HEK293 LAT1 cells. The data values were converted to percentages by normalizing to the average uptake in the vehicle treated cells.
Trans-stimulation is similar to the uptake assay except that the HEK293 LAT1 cells were preloaded for 3 min at 37 °C with transport buffer containing 1-µM 3[H]-phenylalanine as a radiotracer. The cells were then washed with pre-warmed transport buffer, after which SK4 (1 mM) was incubated with the cells for 3 min. Under such conditions, external LAT1 substrates are transported into cells, while LAT1 substrates are exported from cells as part of the overall antiporter transport cycle. Cell washing, lysis and scintillation counting were then performed similar to what is described (Dickens et al. 2013, 2017) for performing the uptake assay.
Electrochemical detection of nitric oxide
Interaction of the SK compounds with nitric oxide (·NO) was detected by the application of a ·NO-sensitive electrode (AmiNO-700, Innovative Instruments, Tampa, FL, USA), as previously described (Schildknecht et al. 2011). The SK compounds (50 µM in 10-mM PBS, pH 7.4,) were incubated with the ·NO-donor Spermine-NONOate (10 µM) (Cayman Chemicals, Ann Arbor, MI, USA). Measurements were performed in glass tubes at 37 °C, and all samples contained 100-µM desferoxamine to exclude any contribution of iron to the observed effects. As the release of ·NO by Spermine-NONOate is temperature dependent, the freshly prepared ice-cold Spermine-NONOate was injected into pre-warmed (37 °C) PBS/compound mixture (990 µl). This procedure leads to an almost linear increase in ·NO release within the first few minutes after injection, followed by a steady-state phase, characterized by a slow but gradual decline in ·NO release in consequence to Spermine-NONOate’s half-life time of ca. 45 min (Maragos et al. 1991). In the present experiment, the initial linear increase was detected. As positive controls, we used xanthine oxidase (1 mU/ml) together with its substrate hypoxanthine (500 µM), a superoxide-generating system.
Interaction of SK compounds with superoxide or peroxynitrite
With the experiments conducted in 96-well plates, interaction between the SK compounds (50 µM) and superoxide was monitored as the oxidation of dihydroethidium (DHE) (5 µM, Sigma-Aldrich). SK compound interaction with peroxynitrite was monitored by detecting dihydrorhodamine (DHR) 123 (1 µM, Sigma-Aldrich) oxidation in PBS (10 mM). Peroxynitrite was generated by Sin-1 (50 µM), superoxide was generated by xanthine oxidase (1 mU/ml) (Sigma-Aldrich) in combination with its substrate, hypoxanthine (500 µM, LKT Laboratories, St. Paul, MN, USA). Freshly prepared Sin-1 or xanthine oxidase was stored on ice and added to pre-warmed buffer/compound for 20 min at 37 °C. Fluorescence of DHR 123 (λex = 485 nm, λem = 538 nm) and DHE (λex = 485 nm, λem = 575 nm) was read using a TECAN Infinite 200 microplate reader (Männedorf, Switzerland).
Interaction of SK compounds with hydroxyl (·OH) radicals
In 96-well plates, hydroxyl radicals (·OH) were generated by combining FeSO4 (20 µM) and H2O2 (50 µM) in H2O. For the readout, desoxyribose (5 mM) was added for the interaction with ·OH to form malondialdehyde. The SK compounds and desferoxamine, were added at the concentrations indicated in the graphical display of the data and incubated for 15 min at RT. The amount of malondialdehyde formed was then detected by the combination of 1/3 volume sample mix, 1/3 volume trichloroacetic acid (2.8 g/100 ml) and 1/3 volume of thiobarbituric acid (1 g in 100 ml of 50 mM NaOH). The mixture was boiled for 20 min at 95 °C. Absorption was then measured at 532 nm.
Data handling and statistics
If not mentioned otherwise, all data values are expressed as means ± the standard deviation (SD). If not indicated otherwise, experiments were performed at least three times (i.e., using three different cell preparations), with at least three technical replicates per condition. Statistical methods for analyzing the various data sets are indicated directly in the figure legends.
Design rational of novel iron chelators
Here, we used the structure of the LAT1 substrate L-DOPA, as well as features of the iron-chelating HOPOs as the basis for designing brain-permeable iron chelators. For this purpose, the aromatic ring of L-DOPA (catechol group) was replaced by a metal chelator moiety, which is similar to DFP (Fig. 1a). We hypothesized that such modified amino acids will remain LAT1 substrates and should have clinically favorable CNS-targeting properties. Further structural variations were introduced to some compounds to change their susceptibility to enzymatic inactivation by methylation or glycosylation. Thus, the compounds SK1-5 were designed and synthesized (Fig. 1a, b, S1-4). In addition, two variants of SK4 were designed and produced to provide analogs lacking chelation properties (SK4C1) or LAT1 affinity (SK4C2) (Fig. 1c; S5).
Protection of neurons from erastin-induced ferroptosis
We used a cellular model of programmed cell death mediated by endogenous cellular iron for bioactivity profiling. Ferroptosis (Dixon et al. 2012) was triggered by erastin. This model compound was chosen for the initial screen, as it neither affects iron directly, nor is it known to damage any cellular structures directly (Yang et al. 2014). SK2 and SK4 both protected neurons to a similar extent as DFP, as assessed by the test endpoints resazurin reduction, neurite area and LDH release. SK3 was active, but less potent; SK1 and SK5 completely lacked the ability to protect neurons from ferroptosis following erastin exposure (Fig. 2a–g). The modifications of SK4 showed the expected properties; in this regard, SK4C1, which lacks any metal chelation properties, did not protect neurons against erastin toxicity. In addition, SK4C2, which represents the structural modification to disturb LAT1 transport, retained similar in vitro bioactivity as SK4 (Fig. 2a, d, f).
Biologically relevant features different from iron chelation
The adverse effects of free iron ions in biological systems can be mediated by oxidative stress (Monzani et al. 2019). Therefore, antioxidants often act as false positives in drug discovery programs for identifying effective iron chelators. While antioxidant properties may provide added value to an anti-neurodegenerative drug, one has to be careful during the initial stages of profiling the drug’s properties not to mistake a drug’s protective properties for iron chelation potency. We, therefore, profiled the ability of the SK compounds to directly (independent of iron chelation) scavenge superoxide, nitric oxide, peroxynitrite and hydroxyl radicals. None of the tested compounds reacted with superoxide or nitric oxide (Fig. 3a, b). However, DFP, SK2 and SK4 proved to be peroxynitrite scavengers of similar potency, but clearly less potent than the more well-known scavengers, urate and ascorbate.
Two promising drug candidates, SK2 and SK4, were further profiled in a hydroxyl radical scavenging assay. SK2 was significantly more potent than SK4. Its activity was in a similar range to that of DFO, an iron scavenger known to also have distinct antioxidant properties (Bartesaghi et al. 2004) (Fig. 3a–e). Based on these data, any protection seen with SK2 in a complex bioassay (in vitro or in vivo) may be due either to specific iron chelation or to unspecific radical scavenging. SK4 appeared as a more promising tool compound to test for the specific role of iron in neurodegeneration.
To prove the validity of the “LAT1 substrate” design hypothesis, we assessed the properties of SK4 and the control compound. As expected for a LAT1 substrate, SK4 competed strongly with the phenylalanine uptake of cells overexpressing LAT1, and significantly increased the export of phenylalanine from preloaded cells in the trans-stimulation assay. SK4C2 (same iron chelator features as SK4, but lacking the amino acid group to be recognized by LAT1) was not transported at all (Fig. 4a, b).
Direct iron-chelating properties of SK4
SK4′s chelation properties towards Fe(III), Cu(II) and Zn(II) were determined by spectrophotometric titrations versus pH and compared to the reference standard DFP. As the basis for this, the protonation constants (pKa values) of SK4 were determined (Fig. S6), as chelation properties are dependent on the protonation state of the chelator, and as pKa values for various HOPO-related structures are known to show a broad range of variation (Fig. S7). The co-ordination models and stability constants of the formed complexes with metals (Fe(III), Cu(II) and Zn(II)) were then determined and the chelation potency/efficacy (displayed in terms of non-complexed metal remaining in solution (log[Mn+]nc) was calculated under defined conditions (20-µM chelator, 1-µM metal ion) within the range of pH values relevant for cells (pH 5.5–pH 8) (Fig. 5a). SK4 showed stronger complex formation with Fe3+ than DFP (Fig. 5a), but exhibiting the same 3,4-HOPO complexing moiety, especially at higher pH values (as found e.g. within mitochondria). SK4 also showed affinity for Cu2+ ions, but almost none for Zn2+. Data were also obtained for compound SK3, based on the 1,2.HOPO scaffold, to exemplify the pH dependence of complex formation with Fe3+. The lower pKa values of this ligand favor its chelation properties at lower pH values.
Physicochemical studies in simple medium (0.1-M NaClO4 in this study) give critical information about the metal-chelating ability of ligands, but those cannot be extrapolated to complex biological systems (cells; brain) without caution. We, therefore, also tested the chelation capacity of SK2 and SK4 in a cellular model. Neuronal cultures were exposed to a FeSO4 solution, known to trigger cell death. SK4 protected neurons from iron-induced neurodegeneration. SK2 did not protect the neurons under similar conditions (Fig. 5b, c), in accordance with its lack of iron chelation capabilities under these experimental conditions. In this direct iron exposure test, the biological features (= cell protection) of SK4 and SK2 were obviously very different. Moreover, the radical scavenging property of SK2 was not of sufficient relevance to protect cells from externally added iron ions.
Protection of neurons from MPP+ toxicity by SK compounds
We further characterized the compounds in the well-established parkinsonian MPTP/MPP+ model. As reported previously (Krug et al. 2014), dopaminergic neurons exposed to 5 μM of the mitochondrial toxicant MPP+ undergo apoptosis within 72 h, and this cell death can be prevented by iron chelators (Poltl et al. 2012). Cell death induced by MPP+ in our model system was assessed by the reduction of the neurite area and an increase in LDH release (Fig. 6a). SK2 and SK4 protected neurons at > 10 µM, and protection was similar to that of DFP. SK3 was less potent; whereas, SK1 completely lacked the ability to protect neurons from MPP+-induced cell death (Fig. 6b–e). SK4C1 also showed a very poor protecting activity (minor effect at ≥ 200 µM) (Fig. 6b, d). Furthermore, we found in an additional experiment that SK4 and DFP rescued dopaminergic neurons even when applied 2 h after the toxicant (Fig. S8).
Protection of neurons from 6-hydroxydopamine toxicity by SK4.
A further well-established model is based on the incubation of dopaminergic neurons with 6-hydroxydopamine (6-OHDA). The corresponding in vivo model shows several key characteristics of neurodegeneration in PD (Lindholm et al. 2007; Salari and Bagheri 2019; Ungerstedt 1973). The damage initiated by 6-OHDA involves oxidative stress to neurons, with endogenous iron levels being important contributors to this damage mechanism (Shachar et al. 2004; Workman et al. 2015; Youdim et al. 2004). When neurons were incubated with 6-OHDA, cells lost their neurites within 24 h; while, somata stayed intact and viable (Fig. 7a). This specific neurite degeneration was significantly reduced by SK4 (≥ 100 µM) and DFP (≥ 50 µM) (Fig. 7a, b). Also SK2 reduced the damage (at ≥ 50 µM); at very high concentrations (200 µM), its effect was more pronounced than the profile produced by either SK4 or DFP (Fig. 7c). All other compounds tested did not show any effect on neurite loss following 6-OHDA exposure (Fig. 7b, c).
Protection of neuronal organoids by SK4 from ferroptosis
To gain insight into the potential protective effect of SK4 on the tissue level, we established a 3D neuronal model for erastin-triggered neurodegeneration. Neuronal spheroids were generated within 10 days. After complete differentiation and neurosphere formation, the organoids were pretreated with protective compounds for 1 h and then exposed to erastin for 24 h (Fig. 8a). To analyze the damage, viable structures were visualized by staining with calcein-AM or immunostaining of neurofilament heavy chains (NF200). The overall neurite area was analyzed to assess putative protective effects by the SK compounds (Fig. 8b–d). The anti-ferroptotic agent Fer-1 (Miotto et al. 2020) protected spheroids from neurodegeneration. A similar protective effect was also observed for the iron chelators DFO and SK4 (Fig. 80c, d).
Here, we present data on the physicochemical characterization as well as cellular investigations of novel iron chelators produced in our laboratories. Neuroprotective properties were investigated using established PD- and iron overload in vitro models that utilized human LUHMES neuronal cultures. The cells were challenged with various toxicants that recapitulate aspects of PD, including dopaminergic cell death, oxidative stress and mitochondrial functional defects (Schildknecht et al. 2017). Potential iron-chelator drug candidates were also protective in a neuronal ferroptosis model, as well as in a direct iron overload paradigm. As SK4 consistently provided neuroprotection against various cytotoxic conditions, our work suggests that this chemical is a useful new tool to further elucidate the mechanistic role of iron in neurodegenerative processes. Moreover, it indicates new strategies to develop brain-targeted metal chelators.
Iron chelators have been deemed therapeutically useful in PD and other neurodegenerative conditions (Dunaief 2011; Joppe et al. 2019; Kaindlstorfer et al. 2018; Ndayisaba et al. 2019). However, their exact effects on brain pathophysiology have not been fully elucidated. One important hypothesis is that the abnormally high labile iron levels in the nigrostriatal system of PD patients contribute to a heightened pro-oxidant environment that impacts on vulnerable dopaminergic neurons found in the SNpc. In this regard, iron-dependent oxidative stress has been demonstrated in vitro, in parkinsonian animal models and also in post-mortem brains of PD patients (Devos et al. 2014; Kaur et al. 2003; Ward et al. 2014; Zheng et al. 2005). In this context, it is important to note that iron-dependent pathology may be triggered without additional iron to an experimental system or human tissue. Brain cells contain mM concentrations of overall iron, mostly bound to ferritin (Reinert et al. 2019; Workman et al. 2015). If only a small fraction of such iron is mobilized, i.e., transferred to the redox-active labile iron pool (LIP), iron-dependent toxicity, and an iron-dependent form of programmed death termed ferroptosis, can ensue (Stockwell et al. 2017). Alternatively, iron can change its role in a cell without increasing ferric iron concentrations. When the overall oxidant–antioxidant balance is shifted, normally innocuous iron concentrations can take on pathological roles, where this can be counteracted again either by activating the cell’s antioxidant defence system (Liddell and White 2018) or by the use of iron chelators. This background explains why iron plays a role in several toxin-based models of mitochondrial impairment and oxidative stress (Poltl et al. 2012; Santiago et al. 1997). In line with this, SK4 fully protected differentiated LUHMES cells against the differently acting toxicants MPP+ and 6-OHDA.
Although it remains unresolved, whether oxidative stress can be considered a primary cause of the neuronal death seen in neurodegenerative disease patients or as a bystander in the progressive neurodegenerative cascade (Andersen 2004), increased iron levels have been shown to directly catalyze ROS production during dopamine synthesis (Rhodes and Ritz 2008). Many forms of neurodegenerations are also accompanied by the production of peroxynitrite (Schildknecht et al. 2013). This highly reactive chemical species, formed by recombining NO with superoxide, interacts directly with a variety of biological targets to exert irreversible damage to all classes of biomolecules (Weidinger and Kozlov 2015). As the cellular damage is strongly driven by peroxynitrite in some model systems, it is important to verify, whether a novel agent can be regarded as a direct scavenger of this molecule or other reactive oxygen/nitrogen species. However, such issues for complicating interpretation of compounds’ mechanism of action do not apply to LUHMES culture systems. This is since these cells do not produce endogenous peroxynitrite due to their very low NO synthase activity (Schildknecht et al. 2015). Thus, our data showing that SK4 is not a potent antioxidant is a clear indication that this compound’s ability to protect against MPP+ and 6-OHDA neurotoxicity must be due to its iron chelation effects.
In the area of experimental pharmacology and for proof-of-concept studies, it is rather important that iron chelators have no other targets and activities. This is the only way to provide clear evidence for a causal role of iron in neurodegeneration models. In this context, the finding that SK4 does not interact with all major reactive oxygen species is of importance. Moreover, the protection from cell death in multiple tests by the non-antioxidant iron chelator SK4 strongly suggests a causal involvement of iron in all these models of neurodegeneration. For a novel metal chelator to be regarded as having potential clinical value for treating the brain degenerating disorder PD, the drug should inherently possess the ability to effectively cross the BBB. Several FDA-approved iron chelators, including deferoxamine (Okauchi et al. 2009) and DFP (Boddaert et al. 2007) may cross the BBB to some extent. Drugs that accumulate passively in brain tissue or that are actively transported across the BBB are of interest, as long-term iron chelation may have adverse side effects in the body periphery. SK1-4 were designed to be substrates of the LAT1 transporter, which is highly expressed in brain capillary endothelial cells. This carrier is responsible for transporting large neutral amino acids, including phenylalanine, tyrosine and leucine, across the BBB in a sodium-ion-independent manner (Matsuo et al. 2000). The same transport system allows transfer of the hydrophilic drug levodopa, a precursor for dopamine, into the brain (Smith and Takasato 1986), with our compounds that were designed to mimic the chemical features of L-DOPA, to be recognized by LAT1. We experimentally validated our structural design hypothesis by showing that SK4 is transported into LAT1 expressing cells. In this respect, the SK compound differs from the clinically approved iron chelators, desferrioxamine (DFO), DFP, and deferasirox (ICL-670), which rather transgress the BBB via passive diffusion (Zhou et al. 2012).
Iron chelation therapy has its origins in the treatment of iron-overload syndromes such as the thalassemias. For these inherited blood disorders, the reduction of an iron overload has clearly proven to be clinically beneficial (Mobarra et al. 2016). However, the scenario is less clear for PD, where clinical trials have only been partially successful. One explanation may be that current drug delivery methods are not optimized for yielding high chelator concentrations in the CNS. More targeted drug delivery methods hold clear advantages for improving clinical outcomes, including reducing drugs’ side effects in the periphery. Our study provides proof-of-concept for a novel delivery approach. Other drug properties may also play important roles. Each metal chelator has a specific “activity” fingerprint, concerning the affinity to ferric iron vs ferrous iron vs several other metal ions (Cu+, Zn2+, etc.), concerning the Ph dependence of such affinities, and the competition with cellular iron-chelating structures, especially in the active center of metalloenzymes. In this regard, it may prove to be a neuroprotective advantage to inactivate certain prolyl hydroxylases by removing their iron (Karuppagounder et al. 2016); on the other hand, it may be detrimental to inactivate catalase or mitochondrial respiratory chain complexes. For this reason, drug candidates appearing similar in terms of their interaction with ferric iron may prove to have largely different drug properties. In the absence of more information on what the optimal profile should look like, it is important to have a large panel of diverse iron chelators available for pharmacological studies. The novel SK compounds, and in particular SK4, contribute to this important objective.
Bovine serum albumin
Fetal bovine serum
Fibroblast Growth Factor 2
Glial-derived neurotrophic factor
Large neutral amino acid transporter
- MPP+ :
Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
Pantothenate kinase-associated neurodegeneration
Unified Parkinson Disease Rating Scale
Reactive oxygen species
Substantia Nigra pars compacta
Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10(Suppl):S18–25. https://doi.org/10.1038/nrn1434
Baes CF, Mesmer RE (1986) The hydrolysis of cations. R.E, Krieger, Malabar, Fla
Bartesaghi S, Trujillo M, Denicola A, Folkes L, Wardman P, Radi R (2004) Reactions of desferrioxamine with peroxynitrite-derived carbonate and nitrogen dioxide radicals. Free Radic Biol Med 36(4):471–483. https://doi.org/10.1016/j.freeradbiomed.2003.10.011
Blum D, Torch S, Lambeng N et al (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65(2):135–172. https://doi.org/10.1016/s0301-0082(01)00003-x
Boddaert N, Le Quan Sang KH, Rotig A et al (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110(1):401–408. https://doi.org/10.1182/blood-2006-12-065433
Chaves S, Piemontese L, Hiremathad A, Santos MA (2018) Hydroxypyridinone derivatives: a fascinating class of chelators with therapeutic applications—an update. Curr Med Chem 25(1):97–112. https://doi.org/10.2174/0929867324666170330092304
Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39(6):889–909. https://doi.org/10.1016/s0896-6273(03)00568-3
de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–S23
Devos D, Moreau C, Devedjian JC et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21(2):195–210. https://doi.org/10.1089/ars.2013.5593
Dickens D, Chiduza GN, Wright GS, Pirmohamed M, Antonyuk SV, Hasnain SS (2017) Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep 7:43580. https://doi.org/10.1038/srep43580
Dickens D, Webb SD, Antonyuk S et al (2013) Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol 85(11):1672–1683. https://doi.org/10.1016/j.bcp.2013.03.022
Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384–386. https://doi.org/10.1212/01.wnl.0000247740.47667.03
Dunaief JL (2011) Ironing out neurodegeneration: iron chelation for neuroprotection. Free Radic Biol Med 51(8):1480–1481. https://doi.org/10.1016/j.freeradbiomed.2011.05.009
Dusek P, Schneider SA, Aaseth J (2016) Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol 38:81–92. https://doi.org/10.1016/j.jtemb.2016.03.010
Efremova L, Schildknecht S, Adam M et al (2015) Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism. Br J Pharmacol 172(16):4119–4132. https://doi.org/10.1111/bph.13193
Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M (2012) alpha-Synuclein expression is modulated at the translational level by iron. NeuroReport 23(9):576–580. https://doi.org/10.1097/WNR.0b013e328354a1f0
Fish WW (1988) Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Methods Enzymol 158:357–364. https://doi.org/10.1016/0076-6879(88)58067-9
Gans P, Sabatini A, Vacca A (1996) Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs. Talanta 43(10):1739–1753. https://doi.org/10.1016/0039-9140(96)01958-3
Gillet R, Roux A, Brandel J et al (2017) A bispidol chelator with a phosphonate pendant arm: synthesis, Cu(II) complexation, and (64)Cu labeling. Inorg Chem 56(19):11738–11752. https://doi.org/10.1021/acs.inorgchem.7b01731
Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson's–divergent causes, convergent mechanisms. Science 304(5674):1120–1122. https://doi.org/10.1126/science.1098966
Grolez G, Moreau C, Sablonniere B et al (2015) Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurol 15:74. https://doi.org/10.1186/s12883-015-0331-3
Gutbier S, May P, Berthelot S et al (2018a) Major changes of cell function and toxicant sensitivity in cultured cells undergoing mild, quasi-natural genetic drift. Arch Toxicol 92(12):3487–3503. https://doi.org/10.1007/s00204-018-2326-5s
Gutbier S, Spreng AS, Delp J et al (2018b) Prevention of neuronal apoptosis by astrocytes through thiol-mediated stress response modulation and accelerated recovery from proteotoxic stress. Cell Death Differ 25(12):2101–2117. https://doi.org/10.1038/s41418-018-0229-x
Harris G, Eschment M, Orozco SP et al (2018) Toxicity, recovery, and resilience in a 3D dopaminergic neuronal in vitro model exposed to rotenone. Arch Toxicol 92(8):2587–2606. https://doi.org/10.1007/s00204-018-2250-8
Hollerhage M, Moebius C, Melms J et al (2017) Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep 7(1):11469. https://doi.org/10.1038/s41598-017-11664-5
Joppe K, Roser AE, Maass F, Lingor P (2019) The contribution of iron to protein aggregation disorders in the central nervous system. Front Neurosci 13:15. https://doi.org/10.3389/fnins.2019.00015
Kaindlstorfer C, Jellinger KA, Eschlbock S, Stefanova N, Weiss G, Wenning GK (2018) The relevance of iron in the pathogenesis of multiple system atrophy: a viewpoint. J Alzheimers Dis 61(4):1253–1273. https://doi.org/10.3233/JAD-170601
Karuppagounder SS, Alim I, Khim SJ et al (2016) Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med 8(328):328ra29. https://doi.org/10.1126/scitranslmed.aac6008
Kaur D, Andersen J (2004) Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev 3(3):327–343. https://doi.org/10.1016/j.arr.2004.01.003
Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37(6):899–909. https://doi.org/10.1016/s0896-6273(03)00126-0
Krug AK, Gutbier S, Zhao L et al (2014) Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+). Cell Death Dis 5:e1222. https://doi.org/10.1038/cddis.2014.166
Lees AJ (2009) The Parkinson chimera. Neurology 72(7 Suppl):S2–11. https://doi.org/10.1212/WNL.0b013e318198daec
Levin JZ, Berger MF, Adiconis X et al (2009) Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol 10(10):R115. https://doi.org/10.1186/gb-2009-10-10-r115
Lhermitte J, Kraus WM, McAlpine D (1924) Original Papers: on the occurrence of abnormal deposits of iron in the brain in Parkinsonism with special reference to its localisation. J Neurol Psychopathol 5(19):195–208. https://doi.org/10.1136/jnnp.s1-5.19.195
Liddell JR, White AR (2018) Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease. Neurochem Int 117:126–138. https://doi.org/10.1016/j.neuint.2017.05.016
Lindholm P, Voutilainen MH, Lauren J et al (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448(7149):73–77. https://doi.org/10.1038/nature05957
Luthman J, Fredriksson A, Sundstrom E, Jonsson G, Archer T (1989) Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav Brain Res 33(3):267–277. https://doi.org/10.1016/s0166-4328(89)80121-4
Malkus KA, Tsika E, Ischiropoulos H (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 4:24. https://doi.org/10.1186/1750-1326-4-24
Maragos CM, Morley D, Wink DA et al (1991) Complexes of. NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 34(11):3242–3247. https://doi.org/10.1021/jm00115a013
Martin-Bastida A, Ward RJ, Newbould R et al (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Sci Rep 7(1):1398. https://doi.org/10.1038/s41598-017-01402-2
Matsuo H, Tsukada S, Nakata T et al (2000) Expression of a system L neutral amino acid transporter at the blood-brain barrier. NeuroReport 11(16):3507–3511. https://doi.org/10.1097/00001756-200011090-00021
Miotto G, Rossetto M, Di Paolo ML et al (2020) Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol 28:101328. https://doi.org/10.1016/j.redox.2019.101328
Mobarra N, Shanaki M, Ehteram H et al (2016) A review on iron chelators in treatment of iron overload syndromes. Int J Hematol Oncol Stem Cell Res 10(4):239–247
Monzani E, Nicolis S, Dell'Acqua S et al (2019) Dopamine, oxidative stress and protein-quinone modifications in parkinson's and other neurodegenerative diseases. Angew Chem Int Ed Engl 58(20):6512–6527. https://doi.org/10.1002/anie.201811122
Ndayisaba A, Kaindlstorfer C, Wenning GK (2019) Iron in neurodegeneration—cause or consequence? Front Neurosci 13:180. https://doi.org/10.3389/fnins.2019.00180
Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G (2009) Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke 40(5):1858–1863. https://doi.org/10.1161/STROKEAHA.108.535765
Poltl D, Schildknecht S, Karreman C, Leist M (2012) Uncoupling of ATP-depletion and cell death in human dopaminergic neurons. Neurotoxicology 33(4):769–779. https://doi.org/10.1016/j.neuro.2011.12.007
Reinert A, Morawski M, Seeger J, Arendt T, Reinert T (2019) Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci 20(1):25. https://doi.org/10.1186/s12868-019-0507-7
Rhodes SL, Ritz B (2008) Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis 32(2):183–195. https://doi.org/10.1016/j.nbd.2008.07.001
Salari S, Bagheri M (2019) In vivo, in vitro and pharmacologic models of Parkinson's disease. Physiol Res 68(1):17–24. https://doi.org/10.33549/physiolres.933895
Santiago M, Matarredona ER, Granero L, Cano J, Machado A (1997) Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals. J Neurochem 68(2):732–738. https://doi.org/10.1046/j.1471-4159.1997.68020732.x
Schildknecht S, Di Monte DA, Pape R, Tieu K, Leist M (2017) Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP. Trends Pharmacol Sci 38(6):541–555. https://doi.org/10.1016/j.tips.2017.03.010
Schildknecht S, Gerding HR, Karreman C et al (2013) Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem 125(4):491–511. https://doi.org/10.1111/jnc.12226
Schildknecht S, Pape R, Meiser J et al (2015) Preferential extracellular generation of the active parkinsonian toxin MPP+ by transporter-independent export of the intermediate MPDP+. Antioxid Redox Signal 23(13):1001–1016. https://doi.org/10.1089/ars.2015.6297
Schildknecht S, Pape R, Muller N et al (2011) Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 286(7):4991–5002. https://doi.org/10.1074/jbc.M110.169565
Schildknecht S, Poltl D, Nagel DM et al (2009) Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol 241(1):23–35. https://doi.org/10.1016/j.taap.2009.07.027
Scholz D, Poltl D, Genewsky A et al (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119(5):957–971. https://doi.org/10.1111/j.1471-4159.2011.07255.x
Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46(2):254–263. https://doi.org/10.1016/j.neuropharm.2003.09.005
Singh N, Ecker GF (2018) Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1, LAT1. Int J Mol Sci. https://doi.org/10.3390/ijms19051278
Skoog DA, Skoog DA (2004) Fundamentals of analytical chemistry, 8th edn. Thomson-Brooks/Cole, Belmont
Smith QR, Takasato Y (1986) Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann N Y Acad Sci 481:186–201. https://doi.org/10.1111/j.1749-6632.1986.tb27150.x
Stockwell BR, Friedmann Angeli JP, Bayir H et al (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171(2):273–285. https://doi.org/10.1016/j.cell.2017.09.021
Terron A, Bal-Price A, Paini A et al (2018) An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. Arch Toxicol 92(1):41–82. https://doi.org/10.1007/s00204-017-2133-4
Ungerstedt U (1973) Selective lesions of central catecholamine pathways: application in functional studies. Neurosci Res (N Y) 5:73–96. https://doi.org/10.1016/b978-0-12-512505-5.50010-0
Vigouroux S, Briand M, Briand Y (2004) Linkage between the proteasome pathway and neurodegenerative diseases and aging. Mol Neurobiol 30(2):201–221. https://doi.org/10.1385/MN:30:2:201
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13(10):1045–1060. https://doi.org/10.1016/S1474-4422(14)70117-6
Weidinger A, Kozlov AV (2015) Biological activities of reactive oxygen and nitrogen species: oxidative stress versus signal transduction. Biomolecules 5(2):472–484. https://doi.org/10.3390/biom5020472
William Langston J (1985) Mechanism of MPTP toxicity: more answers, more questions. Trends Pharmacol Sci 6:375–378. https://doi.org/10.1016/0165-6147(85)90176-2
Workman DG, Tsatsanis A, Lewis FW et al (2015) Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators. Metallomics 7(5):867–876. https://doi.org/10.1039/c4mt00326h
Yang WS, SriRamaratnam R, Welsch ME et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1–2):317–331. https://doi.org/10.1016/j.cell.2013.12.010
Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306–325. https://doi.org/10.1196/annals.1306.025
Zabel C, Nguyen HP, Hin SC, Hartl D, Mao L, Klose J (2010) Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J Proteomics 73(11):2230–2238. https://doi.org/10.1016/j.jprot.2010.08.008
Zheng H, Gal S, Weiner LM et al (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95(1):68–78. https://doi.org/10.1111/j.1471-4159.2005.03340.x
Zhou T, Ma Y, Kong X, Hider RC (2012) Design of iron chelators with therapeutic application. Dalton Trans 41(21):6371–6389. https://doi.org/10.1039/c2dt12159j
Open Access funding provided by Projekt DEAL. This work was supported by the the Doerenkamp-Zbinden foundation, the DFG (KoRS-CB), INVITE and the Projects from the European Union's Horizon 2020 research and innovation programme EU-ToxRisk (Grant Agreement No 681002) and ENDpoiNTs (Grant Agreement No 825759) and by the funding of a PhD studentship by Northumbria University. The work was also made possible by a Royal Society International Exchanges grant awarded to ISP. We are grateful to M. Kapitza, H. Leisner and the staff of the Konstanz Bioimaging Center (BIC), for invaluable experimental support, and several colleagues, in particular G. Fricker and his group in Heidelberg for advice and constructive feedback.
Conflict of interest
The authors declare no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Gutbier, S., Kyriakou, S., Schildknecht, S. et al. Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants. Arch Toxicol (2020). https://doi.org/10.1007/s00204-020-02826-y
- Blood–brain barrier
- Dopaminergic neurons
- Drug design
- Iron chelators
- Parkinson’s disease